We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Potentially Treatable Mutations Discovered in Subset of Prostate Cancer Patients
News

Potentially Treatable Mutations Discovered in Subset of Prostate Cancer Patients

Potentially Treatable Mutations Discovered in Subset of Prostate Cancer Patients
News

Potentially Treatable Mutations Discovered in Subset of Prostate Cancer Patients

Intra-patient tumor heterogeneity makes tissue sampling of the most appropriate index lesion challenging. (A) Baseline PSMA PET/CT demonstrated group of 3 lymph nodes with homogeneously intense uptake with SUVs of 29.7-35.5 (arrows). (B) After 225Ac-PSMA therapy, 2 lesions with SUVs of 29.7 and 32.0 showed morphologic response (green arrows), but index lesion with highest initial uptake (SUV, 35.5) had increased size (red arrow) and persisting PSMA uptake (SUV, 30.0). (C) This lesion (encircled) was chosen for imaging-guided biopsy. Credit: Images created by C Kratochwil and CP Heussel et al., University Hospital Heidelberg, Germany
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Potentially Treatable Mutations Discovered in Subset of Prostate Cancer Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine. In an exploratory study using a relatively new technique—targeted next-generation gene sequencing—researchers found mutations in six out of seven patients with metastatic castration-resistant prostate cancer who did not respond to prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy despite sufficient PSMA expression in their tumors.

Prostate-specific membrane antigen–targeting α-radiation therapy (PSMA-TAT) with 225Ac-PSMA-617 is an emerging and promising approach to treating metastatic castration-resistant prostate cancer. However, a reported 37 percent of patients respond poorly to this therapy even though they have sufficient PSMA expression. Preclinical and early studies suggest that particular DNA damage-repair-associated gene mutations can either increase or decrease the radiosensitivity of prostate cancers and may influence a patient’s response to radiopharmaceutical therapy.

“Given the important role of DNA damage-repair gene alterations, we sought to evaluate the frequency of these defects in patients with an insufficient response to 225Ac-PSMA-617 therapy with next-generation gene sequencing,” said Clemens Kratochwil, MD, supervising physician for radionuclide therapy at Heidelberg University Hospital in Heidelberg, Germany. “A relatively new technique, targeted next-generation sequencing, allows rapid analysis of an individual tumor’s genome. Theoretically, such information can be predictive as to whether a patient has an increased probability to benefit from one specific treatment or combination therapy.”

From a group of 60 patients treated with 225Ac-PSMA-617 PSMA-TAT, researchers identified 10 patients with a poor therapy response despite sufficient PSMA expression. CT-guided biopsies were obtained from seven of the 10 patients and then validated with histopathology and immunostaining. Biopsy specimens were analyzed with two separate targeted next-generation-sequencing panels to detect mutations in 37 genes involved in DNA-damage recognition, checkpoint signaling or DNA-damage repair.

In the seven biopsy specimens, researchers found a total of 15 whole-gene deletions, deleterious mutations and presumably deleterious mutations. Loss of function alterations were found more than once in TP53ATM and CHEK2, with one patient even having a co-mutation of TP53 and CHEK2. Further loss-of-function mutations or whole-gene deletions were detected once in the analyzed sample set for BRCA1BRCA2PMS1NBNMSH2, MSH6, PALB2 and FANCB, respectively. For some other alterations found in ATM, BRCA1, MSH2, SLX4, ERCC and various FANC genes, it was not clear whether they negatively affected its function or were non-pathological variants as part of the normal human diversity.

“Whether the efforts and costs of next-generation sequencing are warranted in a dedicated clinical situation will depend on several factors,” noted Kratochwil. “First, the mutation must be druggable in order to be led to a change in therapeutic management. Second, if the mutations are very rare, then sophisticated testing would not be cost- or time-effective. Lastly, if many patients were found to have comparable mutations, individual testing could be avoided and a one-size-fits-all approach could be applied. The significance of this preliminary work is in guiding of further research, and our findings will likely lead to a change of research practice in the near future.”

He continued, “Once it can be confirmed that a large number of patients receiving PSMA-TAT are simultaneously harboring potentially druggable mutations in genes that are causal related to radio-sensitivity, then clinical evaluation (and hopefully one day routine application) of combination therapies with the potential of over-additive efficacy will become available.”

Reference: Clemens Kratochwil, et al. (2020) Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes. J Nucl Med. DOI: 10.2967/jnumed.119.234559

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement